Dr. Luc Jasmin MD, PhD
Attending Neurosurgeon and a Research Scientist, CEDARS-SINAI MEDICAL CENTER
Member of the Healthcare Council
Council Member Biography
Luc Jasmin, MD, PhD, is an Attending Neurosurgeon and Research Scientist at Cedars Sinai Medical Center in Los Angeles. Dr. Jasmin is involved in a surgical practice and research centered on the treatment of pain and spinal disorders. His clinical work includes cancer spinal surgery as well as treating various pain disorders pharmacologically and surgically such as failed back syndrome, neuropathic pain, cancer pain, and central pain. Dr. Jasmin uses stimulation of the brain and spinal cord as well as the intrathecal pumps to administer various cocktails of drugs. He prescribes a variety of drugs for pain from opiates to anticonvulsants and antidepressants. Dr. Jasmin has also conducted basic research on pain mechanisms and gene therapy for pain. He is a member of several professional societies including American Association of Neurological Surgeons, Royal College of Surgeons, International Association for the Study of Pain, and American Pain Society. (This is me - Update Profile)
Employment History
- 2006 - Unspecified
- Attending Neurosurgeon and a Research Scientist, CEDARS-SINAI MEDICAL CENTER
- 2005 - 2006
- Associate Professor of Neurosurgery, UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
- 2000 - Unspecified
- Assistant Professor of Anatomy, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
GLG NewsSM Analyses by Luc Jasmin(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
TRPs as Analgesic Drug Targets: Using HC-030031 to Probe the Role of TRPA1
September 28, 2009
The 3rd Annual Pain Therapeutics Summit | click.bsftransmit1.com
Transient receptor potential cation channel, subfamily A, member 1 (TRPA1) is a cold receptor, somewhat the opposite of the capsaicin receptor (TRPV1), which is a heat receptor. TRPA1 is a chemosensor and it has an abundance of agonists, exogenous (cigarette smoke, etc...) and endogenous (prostaglandins, etc…). All neurons that express TRPA1 also express TRPV1. Stimulating TRPA1 causes pain. Hydra Biosciences is developing TRPA1 antagonists (receptor blocker) to block pain and inflammation.
-
TRPV1 Agonists: 500 Years in Development
September 28, 2009
The 3rd Annual Pain Therapeutics Summit | click.bsftransmit1.com
Qutenza is a flexible film that wraps on the skin and leads to a rapid release of 8% capsaicin. Possible applications: OA, Post-herpetic neuralgia, HIV neuropathy, and diabetic neuropathy. The results show efficacy in both post-herpetic neuralgia and HIV neuropathy as determine by 30% decrease in pain. More trials are being presently conducted. NeurogesX is developing a liquid form is that is works in a much shorter time (5 min instead of the current 30 to 60 min).
-
Antagonists: Are They Too Hot to Handle?
September 28, 2009
The 3rd Annual Pain Therapeutics Summit | click.bsftransmit1.com
Merck TRPV1 Antagonists MK-2295: Results of clinical studies and reasons why it will not make it to market MK-2295 was administered to normal individuals for 14 days. The investigator tested for heat sensitivity by applying a heat probe to the skin or the subjects having taken MK-2295 or placebo. They also immersed their hands in hot water (48 degree C) or asked them to drink hot water. The results were impressive with the subjects taking MK-2295 displaying a raised threshold to heat. The problem is that often they did do not find unpleasant temperatures around 48 degree C.
-
Responsive vs unresponsive depressive patients have similar electrode sites
September 7, 2009
Based on an association between successful and unsuccessful clinical response, the authors present stereotaxic coordinates, allowing standardization of the implantation site.The post-implantation analysis position of the intracerebral quadripolar electrodes was analyzed in twenty patients. Eleven out of 20 patients achieved a significant reduction of their depression scores at 1 year. The responder's electrodes were only slightly more ventral by 1-2 mm. See J Neurosurg (on line) / May 29, 2009.
-
Vertebroplasty vs kyphoplasty vs arcuoplasty
August 20, 2007
Medtronic Buys Kyphon For $3.9 Billion | www.forbes.com
Will the recent purchase of Kyphon by Medtronic signals the end of kyphoplasty? No because arcuoplasty does not restore vertebral height. Vertebroplasty, kyphoplasty and arcuoplasty essentially achieve the same goals, which brings up the question, do we need all three techniques? Arcuoplasty is the safest of a three for lower thoracic and lumbar vertebrae but until Medtronic comes up with a smaller injection needle system, vertebroplasty will be more appropriate for upper thoracic and cervical spinal levels. The arcuate system is market for osteoporotic fractures but could be improved for cancer (metastasis) related fracture.
Leading institutions connect with Luc Jasmin through GLG
GLG Study Groups with Luc Jasmin(?)
| Study Group Name | No. Members |
|---|---|
| Neurologists who Treat Epilepsy (US) | 341 |
| Physicians who Prescribe Opioids | 315 |
| Physicians who Perform Spine Surgery (US) | 250 |
| Physicians who Treat Neuropathy (US) | 135 |
| Opana ER Prescribers (US) | 105 |
GLG Live Meetings with Luc Jasmin(?)
Luc Jasmin has not participated in any GLG Live Meetings.